Navigation Links
FRC Urges FDA to Reject New Abortion Drug Falsely Labeled as an Emergency Contraceptive
Date:6/16/2010

WASHINGTON, June 16 /PRNewswire-USNewswire/ -- Tomorrow, the Food and Drug Administration (FDA) will hold a hearing to consider approval of a new drug application for an abortifacient drug, ulipristal acetate, as an emergency contraceptive, or a new "Plan B."

(Logo: http://photos.prnewswire.com/prnh/20080930/FRCLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO)

Jeanne Monahan, Family Research Council's Director for the Center for Human Dignity, released the following statement urging the FDA to reject the drug application:

"The drug manufacturer's application is very misleading because the chemical makeup of ulipristal is almost identical to mifepristone, popularly known as RU-486, which is primarily an abortifacient. While the drug can act in a way that inhibits ovulation, it also can act as an abortifacient.

"Women deserve to know the truth about drugs that are marketed to them, and the effects the drugs may have on their health and well-being. The FDA must seriously consider the adverse health effects the drug could have on women, in particular infection and severe bleeding as has been seen with RU-486.

"In the words of the American Association of Pro-Life Obstetricians and Gynecologists (AAPLOG), 'Ulipristal acetate is an abortifacient of the same type as mifepristone (RU-486) and... its approval as an emergency contraceptive raises serious health and ethical issues. Furthermore, ulipristal's potential effects on women who used the drug off-label and upon ongoing pregnancies are essentially unexamined and untested.'

"Both ulipristal and mifepristone block the key early pregnancy hormone, progesterone, from functioning properly which effectively starves the embryo. That action potentially can interfere with or end an established pregnancy.

"Women deserve to know what the drug is doing in their body. Preventing human life from beginning is not the same as destroying a life that has already begun. And to many women it is a distinction that makes all the difference.

"We urge the FDA to take seriously its role to protect innocent human life and safeguard the health of American women by rejecting this abortion drug. We also urge a thorough review process to ensure that women's health is not jeopardized just to advance the agenda of the abortion industry."


'/>"/>
SOURCE Family Research Council
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HCD Research Executive Urges Pharmaceutical Industry to Leverage Social Media to Enhance Traditional Marketing Research
2. Mike Burgess Named Head of Oncology Discovery Translational Area for Roches Pharma Research and Early Development (pRED) Organization
3. DEP Urges Medical Facilities to Take Proper Precautions With X-Ray Equipment to Avoid Health Hazards
4. OrthoWorx Urges Warsaws Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland
5. Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans
6. Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients
7. RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgans Drug Importation Plan Puts Seniors at Risk
8. CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
9. DEP Urges Pennsylvanians to Take Precautions to Reduce West Nile Virus Threat
10. McCaughey Urges Use of First NYS Hospital Infection Report
11. Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)...  South Korean-based healthcare product Development Company I.M. Lab ... Kickstarter. The device will educate the user about ,proper, ... efficiency compared to the dated and pricey CPR training ... of the compression for a more informed CPR training. ... raise $5,000. cprCUBE ...
Breaking Medicine Technology:
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
(Date:10/12/2017)... ... , ... In the United States, single-family home owners pay ... York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 a ... rates, which contributes to the relatively lower cost of living in places like ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision Biomedical Technologies , ... the addition of industry sales leader, Thomas (Tom) Slott, as Senior Vice President ... and sales network, direct the efforts of the surgical sales teams, manage contractual ...
Breaking Medicine News(10 mins):